Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abacavir + indinavir
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Abacavir + indinavir is an oral combination of two antiretroviral drugs used as part of combination antiretroviral therapy for the treatment of Human Immunodeficiency Virus (HIV) infection. **Abacavir** is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase, causing chain termination in viral DNA synthesis and preventing replication[1][2][4]. **Indinavir** is a protease inhibitor which prevents the cleavage of HIV gag-pol polyproteins into mature viral proteins required for infectious virus production. Each drug targets a distinct stage of the HIV replication cycle, and they are used together in multi-drug regimens to reduce viral load and risk of resistance[3][4]. There is no known commercial single-tablet or fixed-dose product of abacavir + indinavir; both are dispensed as their individual formulations.
- Brand names
- none
- Other names
- abacavir and indinavirabacavir plus indinavir
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseSLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)PR (Progesterone receptor)
Beyond the preview
Go deeper on abacavir + indinavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abacavir + indinavir.